Last reviewed 2026-04-19 · How we verify

Fluzone HD - Day 0

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
• Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
• Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations (PHASE4)
• Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
• A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
• Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
• Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Fluzone HD - Day 0 CI brief — competitive landscape report
• Fluzone HD - Day 0 updates RSS · CI watch RSS
• Novavax portfolio CI